コンパニオン診断薬「AmoyDx 肺癌マルチ遺伝子 パネル」の …
がん組織から抽出したdna 中の遺伝子変異（egfr 遺伝子変異及びbraf 遺伝子変異）及 びrna 中の融合遺伝子（alk 融合遺伝子及びros1 融合遺伝子）の検出 nsclc 患者への、以下の抗悪性腫瘍剤の適応を判定するための補助に用いる ・egfr 遺伝子変異
Download コンパニオン診断薬「AmoyDx 肺癌マルチ遺伝子 パネル」の …
Information
Domain:
Source:
Link to this page:
Related documents
RT-qPCR guidelines - University of California, Davis
pcrlab.vetmed.ucdavis.eduContamination assessment (DNA or RNA) E Nucleic acid quantification E Instrument and method E Purity (A260/A280) D Yield D RNA integrity: method/instrument E RIN/RQI or Cq of 3 and 5 transcripts E Electrophoresis traces D Inhibition testing (Cq dilutions, spike, or other) E E = essential, D = desirable
SureSelect Target Enrichment System for the Illumina Platform
www.agilent.comthe prepared library DNA. 5 Indexing and Sample Processing for Multiplexed Sequencing This chapter describes the steps to amplify, purify, and assess quality and quantity of the sample libraries. Samples are pooled by mass prior to sequencing. 6 Appendix: Using FFPE-derived DNA Samples This chapter contains recommended protocol modifications
Whole Exome Sequencing and Analysis
www.nisc.nih.govOct 22, 2018 · DNA from FFPE is always damaged to some degree by the harsh chemical treatments used to preserve the tissue. The degree of damage is influenced by a number of factors, the protocol used in fixing the tissue, the length of time the tissue was stored, and the DNA extraction protocol used. Some damage can be repaired, but not all.